8-K: Bausch Health Opts for Cash Settlement of Executive PSUs

Bausch Health Companies Inc. announced it will settle 2023 performance share unit awards for executives Thomas Appio and Seana Carson in cash rather than stock upon their vesting on March 3, 2026.

Summary

• Bausch Health Companies Inc. will pay certain earned 2023 performance share unit (PSU) awards in cash instead of stock upon vesting.
• The affected executives are Thomas Appio and Seana Carson, both named executive officers.
• These 2023 PSUs were originally granted in March 2023, earned over a three-year performance period, and are scheduled to vest on March 3, 2026.
• For Mr. Appio, 1,137,862 2023 PSUs will be settled solely in cash, equal to the market price of the company's common stock on the vesting date.
• For Ms. Carson, 137,922 2023 PSUs will be settled in cash, equal to the market price, as contemplated by paragraph 7(1)(b) of the Income Tax Act (Canada).
• The Talent and Compensation Committee of the Board of Directors amended Mr. Appio's award agreement and authorized an agreement with Ms. Carson.
• The full text of these agreements will be filed in the Form 10-Q for the quarter ending March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, primarily a technical adjustment to executive compensation that manages share dilution but also represents a cash outflow. It does not indicate a change in operational performance or strategic direction.

Positives

• Settling performance share units in cash rather than issuing new shares helps to prevent dilution of the company's common stock.

Negatives

• The cash settlement of these awards will result in a cash outflow from the company to compensate executives.

Future Outlook

The company will file the full text of the amended and restated award agreement for Mr. Appio and the agreement with Ms. Carson in its Form 10-Q for the quarter ending March 31, 2026.

Industry Context

StockSavvy.ai notes that cash settlement of performance share units is a common executive compensation practice. It allows companies to manage potential share dilution that would occur if awards were settled in equity, while still providing executives with the value of their earned compensation. This approach can be particularly relevant for companies focused on maintaining a stable share count.

Comparison to Industry Standards

• Cash settlement of performance-based equity awards is a standard practice across various industries, often employed to manage share dilution and address tax implications for executives.
• Companies like Pfizer and Merck also utilize a mix of cash and equity-settled awards in their executive compensation programs, demonstrating a similar approach to balancing shareholder interests with executive incentives.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to reduced share dilution, but a negative impact from the cash outflow for compensation.
• Executives (Thomas Appio and Seana Carson): Will receive cash for their earned PSUs, potentially offering more immediate liquidity and different tax treatment compared to stock.

Next Steps

• The company will file the full text of the Appio Agreement and Carson Agreement in its Form 10-Q for the quarter ending March 31, 2026.

Key Dates

Recommendation

This filing details a routine executive compensation adjustment from stock to cash settlement for previously earned performance units. While it prevents share dilution, it also represents a cash outflow. The event itself is not indicative of fundamental changes in the company's operational performance or strategic direction, thus a 'hold' recommendation is appropriate as it doesn't present a strong catalyst for significant price movement.

Keywords

Bausch Health, BHC, executive compensation, performance share units, PSUs, cash settlement, stock awards, corporate governance